Omnicell, Inc. (OMCL) EVP Sells $768,443.74 in Stock
Omnicell, Inc. (NASDAQ:OMCL) EVP Robin Gene Seim sold 15,109 shares of the company’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $50.86, for a total transaction of $768,443.74. Following the transaction, the executive vice president now owns 58,144 shares of the company’s stock, valued at $2,957,203.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of Omnicell, Inc. (NASDAQ:OMCL) traded down 0.30% during trading on Wednesday, reaching $50.60. 201,719 shares of the company traded hands. The firm’s 50 day moving average is $45.75 and its 200-day moving average is $41.48. The stock’s market capitalization is $1.90 billion. Omnicell, Inc. has a 12-month low of $30.35 and a 12-month high of $51.97.
Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, July 27th. The company reported $0.02 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.02. The business had revenue of $180.90 million for the quarter, compared to analysts’ expectations of $174.08 million. Omnicell had a negative net margin of 1.14% and a positive return on equity of 0.41%. The business’s revenue was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.38 earnings per share. On average, equities research analysts anticipate that Omnicell, Inc. will post $1.31 earnings per share for the current fiscal year.
A number of analysts recently weighed in on the company. BidaskClub downgraded Omnicell from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies restated a “hold” rating and issued a $40.00 price objective on shares of Omnicell in a report on Sunday, July 30th. Cantor Fitzgerald restated a “buy” rating and issued a $47.00 price objective on shares of Omnicell in a report on Tuesday, July 25th. Craig Hallum increased their price objective on Omnicell from $46.00 to $52.00 and gave the company a “buy” rating in a report on Friday, July 28th. Finally, Dougherty & Co increased their price objective on Omnicell from $45.00 to $49.00 and gave the company a “buy” rating in a report on Friday, July 28th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $49.00.
Hedge funds and other institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC purchased a new position in shares of Omnicell during the fourth quarter valued at about $788,000. Norges Bank bought a new position in shares of Omnicell during the fourth quarter worth $10,913,000. UBS Asset Management Americas Inc. increased its position in shares of Omnicell by 9.2% in the fourth quarter. UBS Asset Management Americas Inc. now owns 188,158 shares of the company’s stock worth $6,378,000 after buying an additional 15,779 shares during the period. First National Bank of Omaha bought a new position in shares of Omnicell during the first quarter worth $865,000. Finally, Louisiana State Employees Retirement System increased its position in shares of Omnicell by 2.7% in the first quarter. Louisiana State Employees Retirement System now owns 15,100 shares of the company’s stock worth $614,000 after buying an additional 400 shares during the period. Hedge funds and other institutional investors own 96.35% of the company’s stock.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.